Startseite
Kongressberichte 2020
ASCO20 Virtual Scientific Meeting
Studies presented at press briefings
Press Briefing May 28
Press Briefing May 28
(Data from the COVID-19 and Cancer Consortium (CCC19) examining mortality and severe illness among patients with cancer who have contracted COVID-19, and use of azithromycin and hydroxychloroquine. (Abstract LBA110))
Jeremy Lyle Warner, Sam Rubinstein, Petros Grivas, et al.
The abstract concludes:
"All-cause 30-day mortality and severe illness in this cohort were significantly higher than previously reported for the general population and were associated with general risk factors as well as those unique to patients with cancer. Cancer type and treatment were not independently associated with increased 30-day mortality. Longer follow-up is needed to better understand the impact of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments."
View the press briefing presentation
--------------------------------------------------------------------------------------------------------------------------------------------------------
(Latest global research on COVID-19 in patients with thoracic cancer examining the impact of specific cancer treatments on outcomes. (Abstract LBA111))
Leora Horn, Jennifer G. Whisenant, Valter Torri, et al.
The abstract concludes:
"With an ongoing global pandemic of COVID-19 our data suggest that patients with thoracic malignancies are at high risk for hospitalization. Updated results to be presented will include impact on specific chemo-IO regimens and number of lines of therapy, which may impact hospitalization and risk of death as well as which therapies administered may impact survival in patients treated for COVID-19."
View the press briefing presentation
--------------------------------------------------------------------------------------------------------------------------------------------------------
(Phase III Keynote-177 trial comparing pembrolizumab to standard therapy as first-line treatment for select patients with advanced colorectal cancer. (Abstract LBA4, Plenary))
Thierry Andre, Kai-Keen Shiu, Tae Won Kim, et al.
The abstract concludes:
"Pembro provided a clinically meaningful and statistically significant improvement in PFS versus chemo as first-line therapy for pts with MSI-H/dMMR mCRC, with fewer treatment-related AEs observed and should be the new standard of care for these pts."
View the press briefing presentation
--------------------------------------------------------------------------------------------------------------------------------------------------------
(Phase III study assessing the efficacy of adjuvant use of targeted agent osimertinib in patients with localized non-small-cell lung cancer and EGFR mutation after complete tumor resection and adjuvant chemotherapy. (LBA5, Plenary))
Roy S. Herbst, Masahiro Tsuboi, Thomas John, et al.
The abstract concludes:
"Adjuvant osimertinib is the 1st targeted agent in a global trial to show a statistically significant and clinically meaningful improvement in DFS in pts with stage IB/II/IIIA EGFRm NSCLC after complete tumor resection and adjuvant chemotherapy, when indicated. Adjuvant osimertinib provides an effective new treatment strategy for these pts."
--------------------------------------------------------------------------------------------------------------------------------------------------------
(Phase III interim analysis examining maintenance treatment with the immunotherapy avelumab after platinum-based first-line chemotherapy in advanced bladder cancer. (Abstract LBA1, Plenary))
Thomas Powles, Se Hoon Park, Eric Voog, et al.
The abstract concludes:
"JAVELIN Bladder 100 met its primary objective, demonstrating significantly prolonged OS with 1L maintenance avelumab + BSC vs BSC alone in advanced UC in all randomized patients and patients with PD-L1+ tumors. Efficacy benefits were seen across all prespecified subgroups, and the safety profile of avelumab was consistent with previous studies of monotherapy."
View the press briefing presentation
--------------------------------------------------------------------------------------------------------------------------------------------------------
(Phase II study looking at avelumab in patients with gestational trophoblastic tumors resistant to chemotherapy. (Abstract LBA6008))
Benoit You, Pierre-Adrien Bolze, Jean-Pierre Lotz, et al.
The abstract concludes:
"TROPHIMMUN is the first trial of immunotherapy in GTT patients. The anti-PD-L1 monoclonal antibody avelumab was effective, with a favorable safety profile compared to chemotherapy, in patients with resistance to mono-chemotherapy. About 50 % patients could be cured of their chemoresistant diseases. Avelumab may be a new therapeutic option."
View the press briefing presentation
--------------------------------------------------------------------------------------------------------------------------------------------------------
The pediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups.
(INFORM study examining use of precision medicine for pediatric cancers with poor prognosis. (Abstract LBA10503))
Cornelis Martinus van Tilburg, Elke Pfaff, Kristian W. Pajtler, et al.
The abstract concludes:
"Pediatric precision oncology in a real world, multi-national setting is feasible. The prioritization algorithm identifies subgroups benefitting from molecularly matched targeted treatment. Still, for the patients without a very high priority target further layers of molecular and functional data should be incorporated in future programs."